Full TitleA phase II trial of Hepatic Ablation of Metastases to Modulate and Enhance immunotherapy Response (HAMMER) in NSCLC
Liver stereotactic ablative radiotherapy (L-SABR) is a standard treatment that uses radiation therapy to target tumors that have spread to the liver while limiting the radiation dose to surrounding organs. L-SABR may also boost the immune response.
In this study, researchers want to see if adding L-SABR to standard immunotherapy (with or without chemotherapy) for non-small cell lung cancer (NSCLC) that has spread to the liver is more effective than standard therapy alone. Participants with stage IV NSCLC being treated with immunotherapy (with or without chemotherapy) will be randomly assigned to receive L-SABR in addition to their standard therapy or continue to receive standard therapy alone.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have NSCLC that has spread to the liver.
- Patients must have more than three sites of metastasis.
- Participants must be planning to begin or have recently begun immunotherapy, with or without chemotherapy.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Paul Romesser at 646-888-2118.